Brilaroxazine
Phase 3Recruiting 0 views this week 0 watching💤 Quiet
Interest: 37/100
37
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Schizophrenia
Conditions
Schizophrenia
Trial Timeline
Jan 24, 2022 → Feb 1, 2025
NCT ID
NCT05184335About Brilaroxazine
Brilaroxazine is a phase 3 stage product being developed by Reviva Pharmaceuticals for Schizophrenia. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05184335. Target conditions include Schizophrenia.
What happened to similar drugs?
20 of 20 similar drugs in Schizophrenia were approved
Approved (20) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
17
Activity
15
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05184335 | Phase 3 | Recruiting |
Competing Products
20 competing products in Schizophrenia